Bone growth stimulator boosts OrthoLogic
This article was originally published in Clinica
OrthoLogic reported sales of $4.9 million in 1994, boosted by US sales of more than $3 million for the OrthoLogic 1000 bone growth stimulator which was approved by the FDA in March last year. By the end of 1994, the US company estimated that it held about 10% of the $480 million annual market for bone growth stimulators.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.